You are here: Industry Insights > msd

News List

EU & NICE authorise MSD's Keytruda for stage III melanoma pharmatimes
December 20, 2018
MSD’s Keytruda has been given a green light for use within the EU as an adjuvant treatment for stage III melanoma, and has also been made available on the NHS.
Merck collaborates to develop vaccines against dengue biospectrumasia
December 17, 2018
Merck and Instituto Butantan have agreed to collaborate to share clinical data and other learnings from their respective dengue vaccine development programs.
FDA grants breakthrough device designation to artificial intelligence software for CTEPH pattern recognition from Bayer and MSD worldpharmanews
December 06, 2018
Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Pattern Recognition...
Immunotherapy extends the life of head and neck cancer patients pharmatimes
December 04, 2018
A new immunotherapy can greatly extend the lives of a proportion of people with advanced head and neck cancer, with some living for three years or more, reports a major new clinical trial.
MSD chalks up two HIV drug approvals in Europe pharmafile
December 03, 2018
MSD has announced the European approval of two of its products for the treatment of HIV: the single-tablet combination Delstrigo (doravirine, lamivudine and tenofovir disoproxil fumarate)
Thousands of lung cancer patients to get NHS access to Keytruda biospectrumasia
November 26, 2018
MSD’s Keytruda should be funded on the NHS via the Cancer Drugs Fund for patients with the certain forms of lung cancer, according to draft guidance from the National Institute for Health
MSD signs $117m deal with Samsung Bioepis over Janssen biosimilar pharmafile
November 20, 2018
American multinational MSD have won a $117 million contract allowing them to supply Samsung Bioepis’ Renflexis to the US Department of Veteran Affairs.
MSD is looking for a digital health solution to empower oncologists by keeping them updated in their field worldpharmanews
November 17, 2018
MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The solution should consider several channels (web, app, email newsletter, social media, etc
Lenvima backed for NHS use to treat liver cancer pharmatimes
November 12, 2018
The Institute has issued a final appraisal document (FAD) recommending the use of Lenvima (lenvatinib) for untreated, advanced, unresectable hepatocellular carcinoma (HCC)
First-line Keytruda shows better overall survival in head & neck cancer pharmafile
October 25, 2018
MSD’s Keytruda (pembrolizumab) made an impact at the European Society for Medical Oncology 2018 Congress as the company unveiled new Phase 3 data into its efficacy in the first-line...

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page